Grünenthal has received Orphan Drug and Rare Pediatric Disease designations from the US Food and Drug Administration for tegacorat, its orally available investigational compound for Duchenne muscular dystrophy.
Tegacorat is a non‑steroidal selective glucocorticoid receptor agonist and modulator designed to provide an alternative to standard glucocorticoid treatments such as prednisone.
Conventional glucocorticoids influence gene expression through transrepression and transactivation pathways.
While transrepression is linked to anti‑inflammatory effects, transactivation is associated with metabolic and growth‑related side effects. SEGRAMs are intended to emphasise anti‑inflammatory activity while reducing dose‑ and duration‑dependent adverse effects.
Although this has not yet been confirmed in clinical trials, the approach may allow more efficacious dosing with fewer side effects than current treatments.
Uli Brödl, Chief Scientific Officer at Grünenthal, said: “With the current standard of care, people affected by DMD, their caregivers and clinicians must constantly balance efficacy and the burden of side effects as they pursue the essential goal of preserving muscle function.
“We aim to address the unmet need for a long‑term therapy option with potent anti‑inflammatory efficacy while reducing dose‑ and duration dependent side effects. The Orphan Drug and Rare Pediatric Disease designations are an important milestone in the development of tegacorat.”
Grünenthal is preparing a phase 2 trial to investigate the efficacy, safety and tolerability of tegacorat in Duchenne muscular dystrophy. The study is expected to begin later in 2026 at centres in the US and Europe.
Duchenne muscular dystrophy affects around 1 in every 5,000 boys born and is caused by mutations in the dystrophin gene. The condition leads to progressive muscle weakness that impacts mobility, breathing and cardiac function.
It is incurable and typically results in death between 21 and 40 years of age. Current treatment options, including glucocorticoids, can slow deterioration but are associated with significant side effects such as cushingoid appearance, weight gain and behavioural changes.
